'Heroes of Chemistry': Developed new drugs and technology to cut heating and cooling bills

21-Aug-2012 - The scientists behind three inventions that touch the lives of millions of people around the world will be inducted into a coveted scientific "Hall of Fame" as the latest Heroes of Chemistry named by the American Chemical Society (ACS. The ceremony, held at the 244th ACS National Meeting & ...

Iron Complex with a Killer Instinct

Iron-containing nucleoside analogs kill tumor cells - organometallic compounds as a new class of drugs

24-Mar-2004 - German researchers have successfully developed a new class of cytostatics that drive cancer cells to programmed suicide (apoptosis): iron-containing nucleoside analogs. With their discovery, the team led by Hans-Günther Schmalz (University of Cologne), Thomas Wieder (University of Tübingen), ...

Novartis awarded Prix Galien in France for innovative cancer therapy, Glivec®

First time award given two years in a row to same pharmaceutical company in one country; 12th Prix Galien overall for Novartis

13-Mar-2002 - Basel, 12 March 2002 – Novartis has been awarded the prestigious Prix Galien in France for the second year in a row, marking the first time that the same pharmaceutical company has won this distinction for two years in succession. This is the 12th time Novartis has been awarded the Prix Galien ...

GPC Biotech Signs Agreement with ICOS to Manufacture Antibodies for Clinical Studies

27-Nov-2001 - GPC Biotech AG (Frankfurt Stock Exchange: GPC) announced the signing of a development and manufacturing agreement with ICOS Corporation (Nasdaq:ICOS), Bothell, WA (USA) for GPC Biotech's anti-MHC class II antibodies. The agreement also includes a non-exclusive license to ICOS' proprietary ...

ABBOTT LABORATORIES TO ACQUIRE VYSIS, INC.

25-Oct-2001 - Abbott Laboratories (NYSE:ABT) and Vysis, Inc. (Nasdaq:VYSI) today announced that the companies have entered into a definitive agreement for Abbott to acquire Vysis, a leading genomic disease management company that develops and markets clinical laboratory products, which provide information ...

Novartis submits supplemental NDA with US FDA for Glivec® for treatment of certain GI tumors

22-Oct-2001 - Novartis announced today that it has submitted a supplementary New Drug Application (sNDA) to the US Food and Drug Administration (FDA), seeking marketing authorisation for its novel drug Glivec® (imatinib)* for the treatment of patients with unresectable (inoperable) and/or metastatic malignant ...

Structural Bioinformatics, Inc. And ChemNavigator Enter Strategic Alliance

07-Sep-2001 - SAN DIEGO, CA - Structural Bioinformatics, Inc. (SBI) and ChemNavigator announced today the signing of an agreement to combine SBI's proprietary technologies in three-dimensional computational proteomics with ChemNavigator's proprietary technologies in chemistry. The collaborative agreement will ...

FDA approves Novartis' Zometa for the treatment of hypercalcemia of malignancy

22-Aug-2001 - Novartis announced today that it has received marketing approval from the US Food and Drug Administration (FDA) for Zometa 4 mg (zoledronic acid for injection), a new generation intravenous bisphosphonate for the treatment of hypercalcemia of malignancy (HCM). HCM is the most common ...

Sales start of MWG-Biotech‘s new Pan® Chromosome 21 Array

30-Jul-2001 - The Pan® Chromosome 21 Array consists of 498 specific gene sequences and contains all genes known for chromosome 21, as well as additional gene sequences whose location is supposed to be on that chromosome. A cooperation with the Max Planck Institute for Molecular Genetics in Berlin around ...

Novartis breakthrough leukemia drug Glivec® (imatinib) receives positive opinion from CPMP, moves closer to EU approval

30-Jul-2001 - Novartis announced today that it has received a positive opinion from the Committee for Proprietary Medicinal Products (CPMP) for the novel agent Glivec (imatinib) Outside the US: Glivec® (imatinib); in the US: Gleevec™ (imatinib mesylate) in the treatment of adult patients with ...